Klaus joined ArchiMed in 2020 as an Operating Partner. He has over 25 years of experience in management consulting and corporate leadership in the Healthcare industry. At ArchiMed, Klaus is particularly focused on the Biotech sector.
Klaus started his career at the Biotechnology and Genomics Center of Novartis Inc. He then joined McKinsey & Company as a Senior Consultant. He co-founded and lead in his function as CFO BioGenerix AG, the biosimilar business of the ratiopharm group. This was followed by Klaus assuming an executive role at Evotec AG, during which he led a major turn-around, including a Nasdaq listing and numerous corporate development activities. Following this, he joined TETEC AG, a pioneer and market leader in cell therapy development and manufacturing, as CEO.
Klaus holds a PhD in Biochemistry from the Max-Planck Institute and an MBA.
Klaus is a German citizen and speaks fluent English.